Capricor Therapeutics faces questions over potential FDA inconsistency in its approach to Duchenne muscular dystrophy treatments. The company is also dealing with executive leadership changes that may reshape its strategic direction.
The article raises concerns about regulatory inconsistencies affecting Capricor Therapeutics' Duchenne muscular dystrophy drug programs, specifically questioning whether the FDA is applying uniform standards across similar drug candidates in this therapeutic area. Additionally, the piece addresses internal corporate upheaval, noting changes in the company's C-suite leadership that may influence future strategy and operations. These dual challenges—regulatory scrutiny and executive transitions—come at a sensitive time for a biotech company focused on rare genetic diseases.
